ROCKVILLE, Md., April 22, 2008 (PRIME NEWSWIRE) -- Cytomedix, Inc. (AMEX:GTF) today announced that it had recently met with the Centers for Medicare and Medicaid Services (CMS) to determine the optimal path forward for obtaining Medicare coverage for its AutoloGel(tm) System. While CMS does not provide specific commitments regarding any future decision on coverage, the Company sought and received from CMS valuable guidance on the data and information that are likely to be useful during any future reconsideration of the Company's request for a National Coverage Determination (NCD) supporting the use of its AutoloGel System on chronic wounds such as diabetic foot ulcers.
